Cargando…

Increased Risk of Cutaneous Diseases in Multiple Myeloma Patients

Introduction Multiple myeloma (MM) is a monoclonal gammopathy characterized by malignant proliferation of plasma cells in the bone marrow, leading to the overproduction of monoclonal immunoglobulins. Knowledge of cutaneous findings associated with multiple myeloma is limited. This study aims to char...

Descripción completa

Detalles Bibliográficos
Autores principales: Buntinx-Krieg, Talayesa, McKee, Ryan M, Eichenfield, Dawn Z, Marsch, Amanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549871/
https://www.ncbi.nlm.nih.gov/pubmed/33062479
http://dx.doi.org/10.7759/cureus.10356
_version_ 1783592866066464768
author Buntinx-Krieg, Talayesa
McKee, Ryan M
Eichenfield, Dawn Z
Marsch, Amanda
author_facet Buntinx-Krieg, Talayesa
McKee, Ryan M
Eichenfield, Dawn Z
Marsch, Amanda
author_sort Buntinx-Krieg, Talayesa
collection PubMed
description Introduction Multiple myeloma (MM) is a monoclonal gammopathy characterized by malignant proliferation of plasma cells in the bone marrow, leading to the overproduction of monoclonal immunoglobulins. Knowledge of cutaneous findings associated with multiple myeloma is limited. This study aims to characterize cutaneous manifestations in patients with MM or monoclonal gammopathy of undetermined significance (MGUS). Methods This is a retrospective study of patients seen at a single institution between January 2000 and January 2019 with a diagnosis of “multiple myeloma,” “monoclonal gammopathy of undetermined significance,” or “smoldering myeloma,” and an on-site dermatology clinic visit. Results Twenty patients met the inclusion criteria. Most patients were male and Caucasian. Comorbid cutaneous malignancies were noted in 65% of patients (n = 13). Basal cell carcinoma (BCC) was characterized in 55% of patients (n = 11), followed by squamous cell carcinoma in 50% of patients (n = 10), and melanoma in 10% of patients (n = 2). Conclusions Patients with monoclonal gammopathy may be predisposed to developing cutaneous malignancies and skin infections. Given the low prevalence of monoclonal gammopathy, larger multi-center studies with a control cohort may be necessary to delineate the significance of these comorbid skin conditions.
format Online
Article
Text
id pubmed-7549871
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-75498712020-10-13 Increased Risk of Cutaneous Diseases in Multiple Myeloma Patients Buntinx-Krieg, Talayesa McKee, Ryan M Eichenfield, Dawn Z Marsch, Amanda Cureus Dermatology Introduction Multiple myeloma (MM) is a monoclonal gammopathy characterized by malignant proliferation of plasma cells in the bone marrow, leading to the overproduction of monoclonal immunoglobulins. Knowledge of cutaneous findings associated with multiple myeloma is limited. This study aims to characterize cutaneous manifestations in patients with MM or monoclonal gammopathy of undetermined significance (MGUS). Methods This is a retrospective study of patients seen at a single institution between January 2000 and January 2019 with a diagnosis of “multiple myeloma,” “monoclonal gammopathy of undetermined significance,” or “smoldering myeloma,” and an on-site dermatology clinic visit. Results Twenty patients met the inclusion criteria. Most patients were male and Caucasian. Comorbid cutaneous malignancies were noted in 65% of patients (n = 13). Basal cell carcinoma (BCC) was characterized in 55% of patients (n = 11), followed by squamous cell carcinoma in 50% of patients (n = 10), and melanoma in 10% of patients (n = 2). Conclusions Patients with monoclonal gammopathy may be predisposed to developing cutaneous malignancies and skin infections. Given the low prevalence of monoclonal gammopathy, larger multi-center studies with a control cohort may be necessary to delineate the significance of these comorbid skin conditions. Cureus 2020-09-10 /pmc/articles/PMC7549871/ /pubmed/33062479 http://dx.doi.org/10.7759/cureus.10356 Text en Copyright © 2020, Buntinx-Krieg et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Dermatology
Buntinx-Krieg, Talayesa
McKee, Ryan M
Eichenfield, Dawn Z
Marsch, Amanda
Increased Risk of Cutaneous Diseases in Multiple Myeloma Patients
title Increased Risk of Cutaneous Diseases in Multiple Myeloma Patients
title_full Increased Risk of Cutaneous Diseases in Multiple Myeloma Patients
title_fullStr Increased Risk of Cutaneous Diseases in Multiple Myeloma Patients
title_full_unstemmed Increased Risk of Cutaneous Diseases in Multiple Myeloma Patients
title_short Increased Risk of Cutaneous Diseases in Multiple Myeloma Patients
title_sort increased risk of cutaneous diseases in multiple myeloma patients
topic Dermatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549871/
https://www.ncbi.nlm.nih.gov/pubmed/33062479
http://dx.doi.org/10.7759/cureus.10356
work_keys_str_mv AT buntinxkriegtalayesa increasedriskofcutaneousdiseasesinmultiplemyelomapatients
AT mckeeryanm increasedriskofcutaneousdiseasesinmultiplemyelomapatients
AT eichenfielddawnz increasedriskofcutaneousdiseasesinmultiplemyelomapatients
AT marschamanda increasedriskofcutaneousdiseasesinmultiplemyelomapatients